Philipps-Universitaet Marburg

7 trials 6 recruiting Academic / non-commercial

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

6 Recruiting

0 Completed trials

1 Countries active

7 Unique IMPs

N/A Results reported

Phase III

Phase II

Phase III: 1 Phase II: 6

Oversight events:

1 temporary halt across 1 trial

View oversight register →

Top indications

Idiopathic pulmonary fibrosis 2 Bronchiectasis 1 Small intestine neuroendocrine tumour 1 Chronic spontaneous urticaria 1

Top IMPs

COLISTIMETHATE SODIUM 1 DEXAMETHASONE 1 EMPAGLIFLOZIN 1 LUTETIUM (177LU) OXODOTREOTIDE 1 PHOSPHOLIPID FRACTION, BOVINE LUNG 1 TEZEPELUMAB 1 TILDRAKIZUMAB 1

All trials

7 total

Investigation of breathable surfactant agent in patients with idiopathic lung fibrosis Pending

2023-508544-22-00 Phase II 1 country PHOSPHOLIPID FRACTION, BOVINE LUNG
Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II stu… Recruiting

2024-513155-32-00 Phase II 1 country TILDRAKIZUMAB
Adjuvant radioligand therapy in neuroendocrine tumors Recruiting

2024-518236-36-00 Phase III 1 country LUTETIUM (177LU) OXODOTREOTIDE
Proof-of-concept study of Empagliflozin in patients with pulmonary arterial hypertension (EmPAH) Recruiting

2024-517009-99-00 Phase II 1 country EMPAGLIFLOZIN
Clinical Trial on PREnatal Dexamethasone In Congenital adrenal hyperplasia Therapy - PREDICT - Recruiting

2024-511702-23-00 Phase II 1 country DEXAMETHASONE
Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-ar… Recruiting

2024-510884-51-00 Phase II 1 country TEZEPELUMAB
Inhalation therapy in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept … Recruiting

2023-509277-22-00 Phase II 1 country COLISTIMETHATE SODIUM

Showing 1–7 of 7 trials

← All sponsors A–Z